TY - JOUR
T1 - The stabilization mechanism of mutant-type p53 by impaired ubiquitination
T2 - The loss of wild-type p53 function and the hsp90 association
AU - Nagata, Yoichi
AU - Anan, Tadashi
AU - Yoshida, Tetsuo
AU - Mizukami, Tamio
AU - Taya, Yoichi
AU - Fujiwara, Toshiyoshi
AU - Kato, Hirohisa
AU - Saya, Hideyuki
AU - Nakao, Mitsuyoshi
N1 - Funding Information:
We thank Drs H Koga and N Araki (Kumamoto University School of Medicine) for their technical assistance; Drs Q Hu, N Aoyama (Kobe University) and C Miyamoto (Roche Research Center) for providing the pCGN expression vector, 248Trp and ap53-deg antibody, respectively; and T Arino for secretarial assistance. This work was supported by a Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Science and Culture, Japan (M Nakao).
PY - 1999/10/28
Y1 - 1999/10/28
N2 - Mutant-type p53 (mt p53) is largely accumulated in cancer cells due to its increased stability. To elucidate the mechanism of mt p53 stabilization, we analysed the turnover of p53 mutated at codon 248 whose alteration is most frequently found in human cancers. Proteasome inhibition induced the accumulation of ubiquitinated mt p53, indicating that the ubiquitinated forms were essentially unstable and degraded by the proteasome. The presence of a small amount of the ubiquitinated mt p53 relative to the abundant non-ubiquitinated form suggested that the mt p53 ubiquitination was a rate-limiting process in the slow turnover. Two phenomena destabilizing mt p53 via the ubiquitin-proteasome degradation were proved to be independent. First, the coexpression of wild-type p53 (wt p53) promoted mt p53 destabilization as feedback regulation. Second, geldanamycin also induced mt p53 destabilization through the dissociation of the protein from hsp90 but not through the restoration of wt p53 function. Neither the mutant-specific conformation nor the N-terminal phosphorylation seemed to contribute directly to the mt p53 stabilization. Further, a two-dimensional gel electrophoresis revealed that most of the post-translationally modified mt p53 was equally subjected to ubiquitination and subsequent proteasomal degradation. These findings are that mt p53 stabilization depends on the ubiquitination due to both the loss of wt p53 function and the hsp90 association.
AB - Mutant-type p53 (mt p53) is largely accumulated in cancer cells due to its increased stability. To elucidate the mechanism of mt p53 stabilization, we analysed the turnover of p53 mutated at codon 248 whose alteration is most frequently found in human cancers. Proteasome inhibition induced the accumulation of ubiquitinated mt p53, indicating that the ubiquitinated forms were essentially unstable and degraded by the proteasome. The presence of a small amount of the ubiquitinated mt p53 relative to the abundant non-ubiquitinated form suggested that the mt p53 ubiquitination was a rate-limiting process in the slow turnover. Two phenomena destabilizing mt p53 via the ubiquitin-proteasome degradation were proved to be independent. First, the coexpression of wild-type p53 (wt p53) promoted mt p53 destabilization as feedback regulation. Second, geldanamycin also induced mt p53 destabilization through the dissociation of the protein from hsp90 but not through the restoration of wt p53 function. Neither the mutant-specific conformation nor the N-terminal phosphorylation seemed to contribute directly to the mt p53 stabilization. Further, a two-dimensional gel electrophoresis revealed that most of the post-translationally modified mt p53 was equally subjected to ubiquitination and subsequent proteasomal degradation. These findings are that mt p53 stabilization depends on the ubiquitination due to both the loss of wt p53 function and the hsp90 association.
UR - http://www.scopus.com/inward/record.url?scp=0033613434&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033613434&partnerID=8YFLogxK
U2 - 10.1038/sj.onc.1202978
DO - 10.1038/sj.onc.1202978
M3 - Article
C2 - 10557093
AN - SCOPUS:0033613434
SN - 0950-9232
VL - 18
SP - 6037
EP - 6049
JO - Oncogene
JF - Oncogene
IS - 44
ER -